Plain-English translation of NCT05532943 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called UMSC01, which uses stem cells from umbilical cord blood to treat multiple sclerosis. The stem cells are given to patients as infusions into the bloodstream and spinal fluid. Researchers want to see if this treatment is safe and whether it can help control MS symptoms in people whose disease hasn't improved with standard medications.
Standard MS medications don't work well enough for everyone, and some patients continue to have relapses or worsening disability despite treatment. This medication is being studied because stem cells may have the ability to reduce inflammation and protect nerve cells, potentially offering a new option for people who haven't responded to existing therapies.
You likely qualify if…
You likely don't qualify if…
The trial has two phases. In Phase I, 6 patients will receive the stem cell treatment to make sure it is safe. If no serious safety problems occur, the trial will move to Phase IIa, where about 35 more patients will be randomly assigned to either receive the treatment with standard MS medication or receive a sham procedure with standard MS medication only. Participants will receive the medication through an infusion into the bloodstream, and then 28 days later through a procedure into the spinal fluid. You will have regular appointments for safety checks and to measure how your disease is responding.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Taiwan